Multiple-Dose, Dose-Escalation Study to Evaluate
Phase 1
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-jRCT2080221342
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Have given written informed consent
-Women must not be pregnant, breastfeeding or be at risk to become pregnant during study participation
-Diagnosis of Rheumatoid Arthritis
-Active Rheumatoid Arthritis
-Current, regular use of Methotrexate, at a stable dose
-Body weight between 40 and 105 kg, inclusive
Exclusion Criteria
-Use of excluded medications (reviewed by study doctor)
-Have medical findings which, in the opinion of the study doctor, put patient at an unacceptable risk for participation in the study
-Have had recent or ongoing infection which, in the opinion of the study doctor put patient at an unacceptable risk for participation
-Evidence of tuberculosis
-Have systemic inflammatory condition other than RA
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method